Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential. See why I think AQST stock is a buy ...
ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future ...
The nasal spray, dubbed neffy, has been filed for use in adults and children weighing 30 mg or more as an alternative to epinephrine injections such as Kaléo’s AUVI-Q and Viatris’ EpiPen ...
Investor's Business Daily on MSN5d
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics.
Paratek Pharmaceuticals to acquire Optinose and its nasal drug-device Xhance for up to $330M, expanding beyond antibiotics ...
Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...
After hours: March 21 at 7:49:24 PM EDT Loading Chart for VTRS ...
Financials are currently not available. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.
The following grid shows how the soft mutation works.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback